Embed Size (px)
Citation preview
KEY SPEAKERS:WHY ATTEND THIS EVENT:• Hear the latest on Phenotypic screening;how target based screening is allowing foridentification of small molecules • See how you can implement a primary cellassay plan through a case study of SAR-driving assay • The latest in GPCR and other ion channeltargeting pathways and how they are beingused in the most recent drug discoveryassays • Adopt accelerated primary cell screeningsystems such as those utilised by GSK • Hear from over 12 big pharma case studysessions
PLUS INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPWednesday 20th November 2013, Marriott Regents Park London, UK
Overcoming the challenges of moving from 2D to 3D Cell based assays in an HCS and HTS environmentHosted by: Anthony Davies, Director, Trinity College Dublin
9.00am - 12.30pm
• Mao Xiang Chen, Biological and Cellular targets,GlaxoSmithKline• Martha Brown, Senior Associate Director, Boehringer-Ingelheim• Xavier Leroy,Director, Actelion• Pamela Tranter, Investigator III, Novartis • Eric Tang, Associate Principle Scientist, AstraZeneca• Fengrong Zuo, Group Leader of Bioassays, Medimmune • Urs Luethi, Senior Lab Head Discovery, Actelion • Steve Ludbrook, Section Head, GlaxoSmithKline• Anthony Davies, Director, Trinity College Dublin• Tyrell Norris, Team Leader – Cellular Reagents & AssayDevelopment, AstraZeneca
www.cellbasedassay.co.uk.co.ukBOOK BY 19TH JULY AND SAVE £300 / BOOK BY 30TH SEPTEMBER AND SAVE £100
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
BOOK
BY
19TH
JULY
AND
SAVE £
300
BOOK
BY 30
TH SE
PTEM
BER A
ND
SAVE £
100
“A well organised conference withsome very interesting and good talks.”Abbott
SMi present their 6th annual... 18TH - 19TH
NOV2013Marriott Regents Park Hotel, London, UK
The latest in Phenotypic, 3D and Ion Channel based cellular assays
Cell Based Assays
• Screening • Pre-clinical research• Pharmacology• Lead discovery technologies• Molecular and cellular biology• Biological technologies
• Lead generation and optimisation• High content analysis• Target identification and validation• Target discovery• In vitro assays• Compound profiling
WHO SHOULD ATTEND? Heads of Department, Directors, Managers, Team Leaders,
Want to know how you can get involved?
Interested in promoting yourservices to this market?
Contact Margaret Mugema, SMi Marketing on
+44 (0) 207 827 6072, or email: [email protected]
Register online at: www.cellbasedassay.co.uk.co.uk • Alternatively fa
Cell Based AssaysDay One | Monday 18th November 2013 www.cellbaseda
8.30 Registration & Coffee
9.00 Chairman's Opening RemarksAnthony Davies, Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin
THE FUTURE OF CELL BASED ASSAYS: PRIMARY PHENOTYPIC ASSAYS
9.10 Expanding the use of primary cell systems in hit identificationand compound profiling• Current focus on translationally-aligned drug discoveryapproaches, together with significant technologyimprovements
• Several case studies of primary cell systems used at GSK• Increased use of phenotypic assays• Primary screening activitiesSteve Ludbrook, Section Head, GlaxoSmithKline
9.50 Phenotypic screening on automated imaging to identify EMTinhibitors• Performing phenotypic rather than a target based screen• Generating a multiparametric readout based on automatedimaging
• Identifying small molecules that block the EMT (Epithelial-to-mesenchyme transition)
• Case studyUrs Luethi, Senior Lab Head Discovery, Actelion
10.30 Morning Coffee
11.00 Improving the physiological relevance of SAR-driving assayswith primary and stem cells • Immortalising cell lines in drug discovery• Overview of primary and stem cells in context of SAR-drivingassays
• Case studiesMartha Brown, Senior Associate Director, Boehringer-Ingelheim
11.40 Development of high-throughput recombinant assays for ENaC drug discovery• ENaC is an important drug target • Robust functional expression of 3 subunits overcoming cellulartoxicity
• Planar array electrophysiology and FLIPR assays • HTS and compound profilingMao Xiang Chen, Biological and Cellular targets,GlaxoSmithKline
12.20 Networking Lunch
3D CELL CULTURE & FUTURE SCREENING TOOLS FOR PRECLINICAL TOXICOLOGY
1.50 Multi-platform analysis approaches for the evaluation of in 3D biological systems in vitro• Practical issues surrounding 3D cell based assays in research • Experimental approaches we have under taken to implementa multiplatform analysis of in vitro assays
• Demonstrate the feasibility of performing assays in anautomated screening environment
Anthony Davies, Director of the High Content Facility, Institute ofMolecular Medicine, Trinity College Dublin
2.30 Translating drug combinations from in vitro to clinic – 2D or 3D cultures?• Introductions to 3D culture methods • Successful translations from traditional 2D methods • AstraZeneca case study Eric Tang, Associate Principle Scientist, AstraZeneca
3.10 Afternoon Tea
3.50 Cell-based Biomarker Assay Platforms in Support of the Clinical Development of Anti-viral Vaccines and mAbs at MedImmune• Overview of the Cell-based Assay Platforms used for VaccineDrug Development at MedImmune
• Development of the Fluorescence-based RSV infectivity andits microneutralization vs MSD-based IgG assays
• Their utility in phase I clinical study as the immunogenicitybiomarkers for the Live Attenuated RSV Vaccine MEDI559
Fengrong Zuo, Principal Scientist, Group LeaderBioassays/Serology, Medimmune Inc
4.20 Using High Content screening to compare 2D Vs 3D cell responses to a panel of chemotherapeutic agents• Current Techniques in 3D culture• Using 3 Assays (the 3D hanging drop technique, 2D, and stemcell side population) to compare different breast cancer lineresponse to drugs
• Description of techniques to isolate glioblastoma stem cellsfrom patients
• Subsequent screening of these lines in 2D Vs 3D andgeneration of compound ‘fingerprints’ for each line
Gareth Griffiths, Chief Scientific Officer, Imagen Biotech
5.00 Chairman's Closing Remarks and Close of Day One
ax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
Day Two | Tuesday 19th November 2013ssay.co.uk.co.uk
Supported by
8.30 Registration & Coffee
9.00 Chairman's Opening RemarksAnthony Davies, Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin
DRUG DESIGN AND TARGETING ION CHANNELS
9.10 Assay development of multi-subunit ion channels for drug discovery screening using MaxCyte electroporation: GABA-a receptors • Assay development for multi-subunit ion channels
• Scalable transient expression using electroporation
• Comparison of multiple assay platforms
Tyrell Norris, Team Leader – Cellular Reagents & AssayDevelopment, AstraZeneca
9.50 Luciferase based Complementation assay to dissect GPCR signalling pathways• GPCR pathways activation
• GRKs, Beta-arrestin 2
• Endosome, Lysozome, internalization
• Biased agonists
Xavier Leroy, Associate Director, Project Leader, Actelion
10.30 Morning Coffee
11.00 Strategies for screening ion channel drug discovery targets • New technologies and applications of automated
electrophysiology platforms
• Approaches for developing Ion channel cell based assays
• The challenges with profiling transient receptor potential (TRP)
ion channels
Pamela Tranter, Investigator III, Novartis
11.40 Exploring capabilities of IonWorks Barracuda for ion channel safety profiling in early stage drug discovery• Increasing throughput and lowering cost
• Detecting slow-acting compounds
• Extending high throughput electrophysiology to Cys-loop
transmitter-gated ion channels
• Optimising assay performance
David Standing, Senior Scientist,GlaxoSmithKline
12.20 Networking lunch
NOVEL TECHNOLOGIES IN CELL BASED ASSAY PLATFORMS
1.50 A new adaptation to the BacMam system
• Introductions to the BacMam system
• Recent applications of the study
• Case study
Michiel Van Diepen, Scientist II, Novartis
2.30 FLIM HCA from Automated Multiwell Plate Assays to Live
Disease Models
• Flourescence lifetime imaging (FLIM)
• Reading protein interactions in automated multiwell plate
readers in live dieases models
• Application of FLIM plate reader to exemplar assay of HIV-Gay
protein aggregation with dose response resulting in Z'>0.5
Paul French, Head of Photonics Group, Imperial College London
3.10 Afternoon Tea
3.30 Use of human pluripotent stem cell derivatives as cardiovascular
disease models
• Human embryonic and induced pluripotent stem cells
• Advantages of high content screening
• Unique characteristics of cardiomyocyte cultures
• Development of cardiotoxicity and cell growth assays
Sian Harding, Head of Myocardial Function Section, Imperial
College London
4.10 Supplying Donated Human Tissue for Cell Based Assays
• Infrastructure needed to delivery human tissue samples
• How tissue is used at UCL
• Industrial collaborators
• Challenges and solutions to high quality tissue provision
Amir Gander, Senior Knowledge Transfer Associate, UCL Medical
School Royal Free Campus
5.00 Chairman’s Closing Remarks and Close of Day Two
POST-CONFERENCE WORKSHOPWednesday 20th November 2013
9.00am - 12.30pmMarriott Regents Park, London, UK
Overcoming the challenges ofmoving from 2D to 3D Cell based
assays in an HCS and HTSenvironment
Hosted by: Anthony Davies,Director, Trinity College Dublin
Overview of workshop:It is becoming increasingly clear that for manyresearch applications that Three Dimensional (3D)cell culture and cell based assay approachesoffer huge advantages over the moreconventional 2D cell culture and assay models.This workshop will provide an overview of the verylatest 3D cell based assay and culturetechnologies and techniques for use inbiomedical research and drug discovery and thekey application areas for these technologies witha focus on HTS and HCS. • To gain an insight into the issues surroundingthis new area of research
• The opportunity of discussing issues and ideasand sharing experiences with other scientists
• Networking opportunities with peer scientistsworking in the same area
Who should attend?Any scientist using or considering the use of 3Dcell culture and assay technologies for the firsttime.
8.30 Registration & Coffee9.00 Welcome & Introductions9.10 An overview of the main application
areas of 3D assay and cell culture technologies
9.45 An appraisal of all of the currently technologies and their key advantage.
10.45 Morning Refreshments11.00 Presentation of research data from a few
selected studies using 3D assay technologies12.10 Q & A and group discussion 12.30 Close of Workshop
About your wokshop leader:Dr Davies received his PhD in molecularCardiology from the Faculty of Medicine,University of Dundee Scotland. Following thecompletion of this research project he joined TheTayside Institute of Child Health, Dundee,Scotland where he focused on the developmentof specialised cell based assays for the study ofhypoxic and ischemic insult in cardiac musclecells and tissues. Dr Davies undertook furtherresearch at the University of Glasgow where hefocused on the development of miniaturised cellbased assays and cellular arrays for use with highthroughput and high content screening. Dr Daviesnow holds a senior position as director of highcontent research facility (Trinity HCA) Departmentof Clinical Medicine Trinity College Dublin whereas part of his work has led a research teamfocused on the development of a novel 3D assaysystem designed for use in HTS and HCS.
SMi PHARMACEUTICALSFORWARD PLANNER 2013
SEPTEMBER
Cancer Vaccines18 – 19 September 2013, London
Geriatric Safe Medicines Summit16th September to 17th September 2013
OCTOBER
Biosimilars & Biobetters1 – 2 October 2013, London
Diabetes1 – 2 October 2013, London
Orphan Drugs14 – 15 October 2013, London
COPD: Novel Therapeutics andManagement Strategies
16 – 17 October 2013, London
European Pharmaceutical Pricing & Reimbursement
21 – 22 October 2013, London
Point of Care Diagnostics - MarketOpportunities and Technology Trents23 – 24 October 2013, London
NOVEMBER
Cell Based Assays18 – 19 November 2013, London
Clinical Trials in CNS18 – 19 November 2013, London
DECEMBER
Cold Chain Distribution3 – 4 December 2013, London
JANUARY
Pharmaceutical Microbiology20 – 21 January 2014, London
Social Media in the PharmaceuticalIndustry
22 – 23 January 2014, London
Quality By Design22 – 23 January 2014, London
Pre-Filled Syringes27 – 28 January 2014, London
FEBRUARY
Parallel Trade10 – 11 February 2014, London
Advances and Progress in Drug Design17 – 18 February 2014, London
MARCH
Superbugs and Superdrugs - A Focus on Antibacterials05 – 06 March 2014, London
Imaging in Cancer Drug Development12 – 13 March 2014, London
Controlled Release12 – 13 March 2014, London
Paediatric Clinical Trials24 – 25 March 2014, London
Adaptive Designs24 – 25 March 2014, LondonSPONSORSHIP AND EXHIBITION
OPPORTUNITIESSMi offer sponsorship, exhibition, advertising and
branding packages, uniquely tailored tocomplement your company’s marketing strategy.Prime networking opportunities exist to entertain,enhance and expand your client base within thecontext of an independent discussion specific to
your industry. Should you wish to join theincreasing number of companies benefiting from
sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or
email: [email protected]
FAX your booking form to +44 (0) 870 9090 712PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd FloorSouth, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at [email protected]
Payment: If payment is not made at the time of booking, then an invoice will be issued and mustbe paid immediately and prior to the start of the event. If payment has not been received thencredit card details will be requested and payment taken before entry to the event. Bookings within7 days of event require payment on booking. Access to the Document Portal will not be given untilpayment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, anotherdelegate to take your place at any time prior to the start of the event. Two or more delegates maynot ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send asubstitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providingthat cancellation is made in writing and received at least 28 days prior to the start of the event.Regretfully cancellation after this time cannot be accepted. We will however provide theconferences documentation via the Document Portal to any delegate who has paid but is unableto attend for any reason. Due to the interactive nature of the Briefings we are not normally able toprovide documentation in these circumstances. We cannot accept cancellations of orders placedfor Documentation or the Document Portal as these are reproduced specifically to order. If we haveto cancel the event for any reason, then we will make a full refund immediately, but disclaim anyfurther liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data ProtectionAct 1998 and we may use this to contact you by telephone, fax, post or email to tell you about otherproducts and services. Unless you tick here □we may also share your data with third parties offeringcomplementary products or services. If you have any queries or want to update any of the datathat we hold then please contact our Database Manager [email protected] orvisit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address onthe attached letter.
Unique Reference Number
Our Reference LVP-087
Terms and Conditions of Booking
DELEGATE DETAILSPlease complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment must be made to SMi Group Ltd, and received before the event, by one ofthe following methods quoting reference P-087 and the delegate’s name. Bookingsmade within 7 days of the event require payment on booking, methods of paymentare below. Please indicate method of payment:
□ UK BACS Sort Code 300009, Account 00936418□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□Valid From □□/□□ Expiry Date □□/□□CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX cardCardholder’s Name:
Signature: Date:I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
DOCUMENTATIONI cannot attend but would like to purchase access to the following DocumentPortal/paper copy documentation Price Total□ Access to the conference documentation on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00(or only £300 if ordered with the Document Portal)
PAYMENT
VENUE Marriott Regents Park Hotel, 128 King Henry's Road, London, NW3 3ST
□ Please contact me to book my hotelAlternatively call us on +44 (0) 870 9090 711, email: [email protected] or fax +44 (0) 870 9090 712
□ Book by 19th July to receive a £300 discount off the conference price□ Book by 30th September to receive a £100 discount off the conference price
EARLY BIRDDISCOUNT
VATVAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on DocumentPortal and Literature Distribution for all UK customers and for those EU customers not supplying a registration number for their own country here: ______________________________________
CONFERENCE PRICESI would like to attend: (Please tick as appropriate) Fee Total
COMMERCIAL ORGANISATIONS
□ Conference and Workshop £2098.00 +VAT £2517.60
□ Conference only £1499.00 +VAT £1798.80
□ Workshop only £599.00 +VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers and access
to the Document Portal containing all of the presentations.
CELL BASED ASSAYS Conference: Monday 18th & Tuesday 19th November 2013, Marriott Regents Park Hotel, London, UK Workshop: Wednesday 20th November 2013, London
4 WAYS TO REGISTERwww.cellbasedassay.co.uk.co.uk
